乙型肝炎病毒相关性肾炎治疗研究进展

doi:10.3969/j.issn.1672-5069.2014.03.032

Abstract

Abstract: Hepatitis B virus-associated glomerulonephritis （HBV-GN） is a common clinical secondary renal disease in China, which is mostly seen in children and young adults. It has been more than 30 years since the discovery of the association between hepatitis B virus（HBV） infection and the occurrence of glomerulonephritis. However,controversy still lie in the treatment of HBV-GN since then. We aim to give a brief introduction of research and progress in the treatment of HBV-GN.

Key words: Chronic hepatitis B, Nephritis, Interferon-alpha, Nucleotide analogue, Treatment

Su Mingxue, Liu Chuanmiao. Progress in the treament of hepatitis B virus-associated glomerulonephritis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 321-325.

References

[1] Combes B,Shorey J,Barrera A,et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet,1971,2（7718）:234-237.
[2] Chan TM. Hepatitis B and renal disease. Curr Hepat Rep,2010,9（2）:99-105.
[3] Xu H,Zhou LJ,Fang LJ,et al. The effect of hepatitis B vaccination on the incidence of childhood HBV-associated nephritis. Pediatr Nephrol,2003,18（12）:1216-1219.
[4] Bhimma R,Coovadia HM,Adhikari M,et al. The impact of the hepatitis B virus vaccine on the incidence of hepatitis B virus-associated membranous nephropathy. Arch Pediatr Adolesc Med,2003,157（10）:1025-1030.
[5] Han SH. Extrahepatic manifestations of chronic hepatitis B. Clin Liver Dis,2004,8（2）:403-418.
[6] Zhang Y,Zhou JH,Yin XL,et al. Treatment of hepatitis B virus-associated glomerulonephritis:a meta-analysis. World J Gastroenterol,2010,16（6）:770-777.
[7] 耿兴花,孙珉丹. 乙型肝炎病毒相关性肾炎的研究进展. 吉林医学,2009,30（15）：1702-1704.
[8] Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int, 1995,47（1）:225-230.
[9] Conjeevaram HS,Hoofnagle JH,Austin HA,et al. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology,1995,109（2）:540-546.
[10] Bhimma R,Coovadia HM,Kramvis A,et al. Treatment of hepatitis B virus-associated nephropathy in blank children. Pediatr Nephrol,2002,17（6）:393-399.
[11] 曹春蕊,尹胜杰,白玉如,等. 干扰素治疗乙肝病毒相关性肾炎的Meta分析. 河北医药,2010,32（3）：325-326.
[12] 孟繁平,龚清,韩军,等. 核苷（酸）类似物抗病毒治疗乙型肝炎病毒相关性肾炎疗效观察. 传染病信息,2010,23（4）：206-208.
[13] Tang S,Lai FM,Lui YH,et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int,2005,68（4）: 1750-1758.
[14] 丁明权. 拉米夫定治疗成人乙肝相关性肾炎11例. 实用医药杂志,2009,26（9）：92.
[15] Ng YY,Yang WC,Lee ST. Long-term lamivudine therapy in hepatitis B-associated membranous nephropathy Kidney Int, 2006,69（4）:776.
[16] Lok AS,Lai CL,Leung N,et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology,2003,125（6）:1714-1722.
[17] 孙希平,杨谦,曹显刚. 阿德福韦酯加糖皮质激素治疗乙型肝炎病毒相关性肾炎29例. 中国医药指南,2010,8（25）：8-11.
[18] 李东复,金珍婧,陈永胜,等. 阿德福韦酯治疗乙型肝炎肝硬化合并乙型肝炎病毒相关性肾炎的近期疗效.中华肝脏病杂志,2008,16（5）：349-351.
[19] 雷红卫. 恩替卡韦与拉米夫定治疗乙型肝炎病毒相关性肾炎的疗效比较. 中国现代医药杂志,2008,10（10）：107-108.
[20] 岳风娥,程华. 恩替卡韦治疗乙型肝炎病毒相关性肾炎2例. 肝脏,2007,12（1）：78.
[21] 肖静,魏二虎,卢珊,等.甲泼尼龙联合恩替卡韦治疗原发性肾病综合征合并乙肝病毒感染的疗效观察. 中国全科医学,2010,13（9B）：2984-2985.
[22] 朱丽君. 恩替卡韦治疗乙肝相关性肾炎30例临床分析.中外医学研究,2012,10（6）：19-20.
[23] Zoulim F,Radenne S,Ducerf C. Management of patients with decompensated hepatitis B virus associated cirrhosis. Liver Transpl,2008,14（10）: S1-S7.
[24] Taskapan H,Oymak O,Dogukan A,et al. Transformation of hepatitis B virus-related membranous glomerulonephritis to crescentic form. Clin Nephrol,2000,54（2）:161-163.
[25] Lai KN,Tam JS,Lin HJ. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron, 1990,54（1）:12-17.
[26] Lai FM,Tam JS,Li PK,et al. Replication of hepatitis B virus with corticosteroid therapy in hepatitis B virus related membranous nephropathy. Virchows Arch A Pathol Anat Histopathol,1989,414（3）:279-284.
[27] Lin CY. Clinical features and natural course of HBV-related glomerulopathy in children. Kidney Int Suppl,1991,35:S46-S53.
[28] 何光向,郑宋明. 乙肝病毒相关性肾炎的诊断与治疗. 浙江中西医结合杂志,2008,18（6）：358-359.
[29] 邓声莉,杨敬华. 来氟米特、泼尼松和贺普丁联合治疗乙型肝炎病毒相关性肾炎的临床研究. 中国医学工程,2006,14（5）：494-496.
[30] Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus,2005,14（1）:S2-S8.
[31] 成彩联,娄探奇,郑振达,等. 霉酚酸酯联合激素及拉米夫定治疗乙肝相关性肾炎的观察. 中国实用内科杂志,2005,25（12）：1083-1085.
[32] 骆丹. 霉酚酸酯联合拉米呋啶治疗乙肝病毒相关性肾炎30例临床分析. 海军医学杂志,2009,30（2）：114-116.
[33] Lin CY,Lo SC. Treatment of hepatitis B virus-associated membranous nephropathy with adenine arabinoside and thymic extract. Kidney Int,1991,39（2）:301-306.
[34] 杨炳中,何杨帆,谭中友,等.拉米夫定、雷公藤总苷联合蝮蛇抗栓酶治疗乙型肝炎病毒相关性肾炎.实用儿科临床杂志,2008,23（5）：379-380.
[35] 段阳日. 拉米夫定、来氟米特和中药联合治疗乙型肝炎病毒相关性膜性肾病的临床研究. 中国现代医生,2011,49（25）：81-82.

Progress in the treament of hepatitis B virus-associated glomerulonephritis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[3]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[4]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[5]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[6]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[7]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[8]	Gao Zhiliang, Zhu Xiang. How to achieve the clinical cure of hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 305-308.
[9]	Wang Xiaoxiao, Chen Xinyue. Therapeutic strategy for serum HBsAg clearance in suitable population of chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 309-312.
[10]	Wang Baodan, Li Meng, Gao Yu. Predictive factors of response to interferon-α antiviral therapy in children with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 345-348.
[11]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[12]	Guideline for diagnosis, treatment of liver failure. [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 164-171.
[13]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[14]	Zhao Xiaofei, Lin Dongdong, Li Ning, Zang Yunjin, Guo Qingliang, Wu Juanshan. Application of warfarin in dealing with portal vein thrombosis in patients with liver cirrhosis after splenectomy and devascularization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 240-243.
[15]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.